Pipeline

Developing novel biologics for autoimmune diseases

Jade’s focus is to develop transformational, disease-modifying therapies targeting autoimmune diseases. The company’s lead candidate, JADE101, is a potentially best-in-class monoclonal antibody designed to inhibit the cytokine APRIL (A PRoliferation Inducing Ligand). A Phase 1 clinical trial evaluating JADE101 in healthy volunteers is ongoing, with interim, biomarker-rich data expected in the first half of 2026. Jade’s pipeline also includes JADE201, an anti-BAFF-R (B-cell activating factor receptor), and an undisclosed antibody discovery program, JADE-003, both currently in preclinical development.

Program
Candidate
Discovery
IND-Enabling
Phase 1
Expected Milestones
Potential Indications

JADE101 is a potential best-in-class monoclonal antibody designed to block the APRIL (A PRoliferation Inducing Ligand) protein, which plays a key role in the development of IgA nephropathy (IgAN), a chronic kidney disease resulting from inflammation and damage that can impair kidney function over time. By targeting the underlying pathogenesis of IgAN, JADE101 is designed to reduce IgA levels, lower protein levels in the urine (a key marker of kidney damage), and preserve long-term kidney function.

Learn more Learn more

JADE201 is a half-life extended, afucosylated monoclonal antibody targeting BAFF-R (B-cell activating factor receptor), a clinically validated pathway in autoimmune disease. It is designed with a dual mechanism of action: blocking BAFF signaling to inhibit B cell survival and enhancing effector functions to directly eliminate B cells.  

MOA: UndisclosedJADE-003
Planned FIH:
1H 2027
Undisclosed
Candidate JADE101
Planned Clinical FIH Interim Data:
1H 2026
Planned Healthy Volunteer Data 1H 2026
Potential Indications IgAN

JADE101 is a potential best-in-class monoclonal antibody designed to block the APRIL (A PRoliferation Inducing Ligand) protein, which plays a key role in the development of IgA nephropathy (IgAN), a chronic kidney disease resulting from inflammation and damage that can impair kidney function over time. By targeting the underlying pathogenesis of IgAN, JADE101 is designed to reduce IgA levels, lower protein levels in the urine (a key marker of kidney damage), and preserve long-term kidney function.

Learn more Learn more
Candidate JADE201
Planned Clinical FIH Planned FIH:
1H 2026
Planned Healthy Volunteer Data Planned FIH:
1H 2026
Potential Indications Multiple systemic AI diseases

JADE201 is a half-life extended, afucosylated monoclonal antibody targeting BAFF-R (B-cell activating factor receptor), a clinically validated pathway in autoimmune disease. It is designed with a dual mechanism of action: blocking BAFF signaling to inhibit B cell survival and enhancing effector functions to directly eliminate B cells.  

Candidate
Planned Clinical FIH Planned FIH:
1H 2027
Planned Healthy Volunteer Data Planned FIH:
1H 2027
Potential Indications Undisclosed